Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Epidemiology guidance

Executive Summary

FDA is considering developing a guidance on the use of epidemiological data in order to facilitate post-marketing surveillance. The document would advise industry on the analysis of large safety databases. The expansion of funding for post-market drug surveillance activities is under discussion as part of the fourth renewal of the Prescription Drug User Fee Act next year (1"The Pink Sheet" Nov. 21, 2005, p. 3)...

You may also be interested in...

PDUFA IV: FDA Stresses Burden Of Industry Meetings In User Fee Discussions

FDA is emphasizing the difficulties of industry requested meetings in its early public discussion of the 2007 Prescription Drug User Fee Act reauthorization

No Korea-Originated New Drugs Approved Domestically In 2023

Notable new drug approvals in South Korea last year included Pfizer’s Tukysa, Genentech’s Columvi and BeiGene’s Tevimbra, but the tally did not include any domestically-originated products. Alzheimer’s disease therapy lecanemab may be on the horizon this year.

New York Begins Restricting Sales Of Supplements, OTC Drugs For Weight Loss, Bodybuilding

Southern New York district judge rejects CRN’s arguments to block regulation from taking effect, but agrees with trade group and its members that they have standing to challenge the regulation. CRN complaint challenging law will continue in the district court.

Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts